Firstly, previous studies reported that regrafenib targets multiple tumor pathways involved in biliary tumorigenesis, including EGFR, RAS, RAF, VEGFR, FGFR, and PDGFR signaling pathways (7–10). This evidence concerns the gene EGFR and neoplasm.